Juan Angel Recio Conde Dr Recio is the Head of the BioMedical Research in Melanoma-Animal Models in Cancer Group at VHIR. His group is very interested in skin cancer. He investigates the molecular causes for these diseases in order to design effective therapies against them. This is done in close proximity to patients where our goal is to translate our discoveries as fast as possible to patients. Consequently, He have a multidisciplinary group that associate dermatologists, oncologists, pathologists and basic-scientists that ask relevant clinical questions that need biological answers. His workflow contemplates reverse translation where information obtained from patients (tumors deep sequencing, immunohistochemistry, clinical history...etc) is translated into animal models and in vitro experiments in order to answer relevant questions. These results are used to design new therapeutic approaches and preclinical studies that ultimately will be translated to patients. This cooperation with the clinic started back in 2007 when he formed a translational group devoted to solve relevant problems in the clinic, which includes conceptual basic mechanisms that can be translated to the patients. In the last ten years with the arrival of the immunotherapy he created the Melanoma Taskforce, a joined effort that puts together oncologists and basic researchers from different fields (immunology, genomics, imaging, etc.) from VHIR, VHIO and the Hospital, with the goal of translate the knowledge to patients through the daily practice, and the cooperation with the industry to improve the efficacy of novel drugs or combinations in clinical trials. His group face problems that start in the primary lesions through the most advance stages of the disease, including samples from clinical trials and different studies. With this structure he has managed to establish a coordinated network within the hospital to develop patient derived xenografts (PDX) from fresh tissue samples and a Biobank of melanoma, saving valuable different type of samples which are the source of information for his research and discoveries. Institucions de les que formen part Cap de grup Recerca Biomèdica en Melanoma Vall Hebron Institut de Recerca LinkedIn Twitter Orcid Juan Angel Recio Conde LinkedIn Twitter Orcid Institucions de les que formen part Cap de grup Recerca Biomèdica en Melanoma Vall Hebron Institut de Recerca Dr Recio is the Head of the BioMedical Research in Melanoma-Animal Models in Cancer Group at VHIR. His group is very interested in skin cancer. He investigates the molecular causes for these diseases in order to design effective therapies against them. This is done in close proximity to patients where our goal is to translate our discoveries as fast as possible to patients. Consequently, He have a multidisciplinary group that associate dermatologists, oncologists, pathologists and basic-scientists that ask relevant clinical questions that need biological answers. His workflow contemplates reverse translation where information obtained from patients (tumors deep sequencing, immunohistochemistry, clinical history...etc) is translated into animal models and in vitro experiments in order to answer relevant questions. These results are used to design new therapeutic approaches and preclinical studies that ultimately will be translated to patients. This cooperation with the clinic started back in 2007 when he formed a translational group devoted to solve relevant problems in the clinic, which includes conceptual basic mechanisms that can be translated to the patients. In the last ten years with the arrival of the immunotherapy he created the Melanoma Taskforce, a joined effort that puts together oncologists and basic researchers from different fields (immunology, genomics, imaging, etc.) from VHIR, VHIO and the Hospital, with the goal of translate the knowledge to patients through the daily practice, and the cooperation with the industry to improve the efficacy of novel drugs or combinations in clinical trials. His group face problems that start in the primary lesions through the most advance stages of the disease, including samples from clinical trials and different studies. With this structure he has managed to establish a coordinated network within the hospital to develop patient derived xenografts (PDX) from fresh tissue samples and a Biobank of melanoma, saving valuable different type of samples which are the source of information for his research and discoveries.
Dr. Recio obtained her PhD at the University Autonomous of Madrid investigating the immunophenotype of the epididymis during development and in inflammatory diseases. During the same period of time he worked simultaneously at Dr Ana Aranda’s lab (IIB , CSIC) investigating the biological consequences of nuclear receptors regulation by retinoic acid and visited Dr. Notario’s Lab at Georgetown University (Washington DC, USA) where he studied the contribution of dioxins to breast cancer development. Then, he moved to Georgetown University as a postdoctoral where he spent almost three years studying the oncogenic transformation of cells. He did his second postdoctoral training at the National Cancer Institute (NIH, Bethesda, MD, USA) joining Dr. Glenn Merlino’s lab where he studied the molecular basis of melanoma and develop the first mouse model of UV-induced melanoma. During this time, he also was involved in the development of other mouse models including the first rhabdomyosarcoma mouse model. Then, in 2005, he obtained a Ramon y Cajal award and moved to Barcelona where he started his own lab at the Vall d’Hebron Institute of Oncology (VHIO), establishing a translational group of Biomedical Research in Melanoma, later, in 2010 he moved to VHIR, where he remains at present time.. Dr Recio have received a number of awards (Fogarty award, NCI_NIH productivity award...) and published more than 40 papers mostly in the melanoma filed including 2 books chapters. He also has continuously obtained a number of competitive national and international grants over the last 20 years, frequently collaborating with the industry. In addition to this he has directed 6 doctoral thesis and supervised more than 20 master projects. He belongs to the biomedicine postgraduate program at the University of Barcelona and the Translational Master at the Vall d’Hebron Institute (University Autonomous of Barcelona). Moreover, he is an expert evaluator for national and International recognized Institutions and Agencies and a member of several scientific and technical boards and committees.
Projectes Beca VHIR PhD IP: Juan Angel Recio Conde Col·laboradors: Beca VHIR PhD, Laia Perez Lasarte, Yuxin Ding Entitat finançadora: Fundació Institut de Recerca HUVH Finançament: 69188.74 Referència: VPHD/YUXUNG_D Durada: 01/09/2023 - 31/08/2026 Development of TET2 activating drugs for the treatment of melanoma IP: Juan Angel Recio Conde Col·laboradors: - Entitat finançadora: Ministerio de Ciencia e Innovación-MICINN Finançament: 233708 Referència: CPP2022-009781 Durada: 01/11/2023 - 31/10/2026 Tumor dependent immune evasive mechanisms in melanoma IP: Juan Angel Recio Conde Col·laboradors: Paula Granado Martinez, Kimberley Anne McGrail Fernández, Vicente García-Patos Briones, Berta Ferrer Fábrega, Yuxin Ding, Roberto Orsenigo Entitat finançadora: Instituto de Salud Carlos III Finançament: 321250 Referència: PI23/00428 Durada: 01/01/2024 - 31/12/2026 Discovering intratumoral immune-cell resistance mechanisms to immunotherapy response IP: Juan Angel Recio Conde Col·laboradors: Roberto Orsenigo Entitat finançadora: Fundació "La Caixa" Finançament: 115092 Referència: CAIXA/INPHINIT/2022/ORSENIGO Durada: 01/11/2022 - 31/10/2025 Paginació Pàgina actual 1 Page 2 Page 3 Page 4 Page 5 … Pàgina següent › Última pàgina »
